SAREPTA THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable and Other Operating Liabilities
SAREPTA THERAPEUTICS, INC. (SRPT) reported Increase (Decrease) in Accounts Payable and Other Operating Liabilities of $21.88 million for the 401-month period ending 2013-12-31, per its 10-K filed 2014-03-03.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities · last filed 2014-03-03
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2013-12-31 was $7.60M, a 105.32% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2013-09-30 was $2.16M.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2012-12-31 was $3.70M.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2012-09-30 was -$4.47M.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts payable and other operating liabilities for fiscal 2013 was $9.47M.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts payable and other operating liabilities for fiscal 2012 was -$1.72M, a 121.49% decline from fiscal 2011.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts payable and other operating liabilities for fiscal 2011 was $8.00M.
| Period end | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 3 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 6 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 9 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 12 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 395 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 398 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 401 month |
|---|---|---|---|---|---|---|---|
| 2013-12-31 | $7.60M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $9.76M derived: sum of 2 quarters · filed 2014-03-03 | $9.47M 10-K · filed 2014-03-03 | $21.88M 10-K · filed 2014-03-03 | |||
| 2013-09-30 | $2.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $1.87M 10-Q · filed 2013-11-12 | $14.28M 10-Q · filed 2013-11-12 | ||||
| 2013-06-30 | -$294.00K 10-Q · filed 2013-08-08 | $12.12M 10-Q · filed 2013-08-08 | |||||
| 2012-12-31 | $3.70M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | -$766.00K derived: sum of 2 quarters · filed 2014-03-03 | -$1.72M 10-K · filed 2014-03-03 | ||||
| 2012-09-30 | -$4.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | -$5.42M 10-Q · filed 2013-11-12 | |||||
| 2012-06-30 | -$952.00K 10-Q · filed 2013-08-08 | ||||||
| 2011-12-31 | $8.00M 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |